SHARED: FDA issues warning letter for not including the most serious risks in advertisement for medication-assisted treatment drug — NationalAddictionNews.com

The U.S. Food and Drug Administration today posted a warning letter to Alkermes, Inc. of Massachusetts, for inaccurately branding the drug Vivitrol (an extended-release injection formulation of naltrexone) by omitting warnings about the most serious risks associated with the drug from promotional materials. Vivitrol is approved for the prevention of relapse to opioid dependence, following …

Advertisement